| Detected | Trial | Change |
|---|---|---|
| 2026-06-06 | NCT06660563 A Study of JNJ-80948543 in Combination With Other CD3 T-Cell Engagers in Participants… |
date change Primary completion moved earlier: 2026-09-07 -> 2026-01-19 |
| 2026-06-06 | NCT06660563 A Study of JNJ-80948543 in Combination With Other CD3 T-Cell Engagers in Participants… |
date change Completion pushed: 2026-09-21 -> 2027-03-31 |
| NCT ID | Title | Condition | Status |
|---|---|---|---|
| Phase 1 | |||
| NCT05424822 | A Study of JNJ-80948543, a T-cell Redirecting CD79b x CD20 x CD3 Trispecific Antibody, in… | Lymphoma, Non-Hodgkin | Active, Not Recruiting |
| NCT06139406 | A Study of JNJ-87801493 in Combination With T-Cell Engagers in Participants With B-cell… | Lymphoma, Non-Hodgkin | Active, Not Recruiting |
| NCT06660563 | A Study of JNJ-80948543 in Combination With Other CD3 T-Cell Engagers in Participants… | Lymphoma, Non-Hodgkin | Active, Not Recruiting |
| NCT06788509 | A Rollover Study for Continued Study Treatment and Ongoing Safety Monitoring | Leukemia, Myeloid, Acute | Enrolling by Invitation |